Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 285-332-6 | CAS number: 85068-73-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 04 February 2020 - 26 February 2020
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 020
- Report date:
- 2020
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
Test material
- Reference substance name:
- 2-(ethylnitroamino)ethyl nitrate
- EC Number:
- 285-332-6
- EC Name:
- 2-(ethylnitroamino)ethyl nitrate
- Cas Number:
- 85068-73-1
- Molecular formula:
- C4H9N3O5
- IUPAC Name:
- ethyl(nitro)[2-(nitrooxy)ethyl]amine
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: VELAZ PRAHA, Czech Republic
- Females nulliparous and non-pregnant: yes
- Age at study initiation: 8-12 weeks
- Weight at study initiation: Range 178-214 g (9 females)
- Fasting period before study: yes
- Housing: The animals were housed in plastic cages suspended on stainless steel racks, up to 3 animals per cage in a room equipped with central air-conditioning.
- Diet (e.g. ad libitum): The laboratory food ssniff (Spezialdiäten GmbH, Germany) was offered at recommended doses each day approximately at the same time.
- Water (e.g. ad libitum): Tap water ad libitum.
- Acclimation period: 5 days.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-25ºC
- Humidity (%): 50-60%
- Air changes (per hr): Not specified.
- Photoperiod (hrs dark / hrs light): 12 hours light/12 hours dark.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 60 mg/mL for the dose of 300 mg/kg bw. Dose of 2000 mg/kg bw was administered directly without vehicle.
- Amount of vehicle (if gavage): 5 mL/kg
- Justification for choice of vehicle: The test item is not soluble enough in water, therefore Olive oil was used as vehicle. Oil is a standard vehicle according to OECD TG 423.
- Lot/batch no.: L91087
MAXIMUM DOSE VOLUME APPLIED: 5 mL/kg bw for the dose of 300 mg/kg bw and 1.5 mL/kg bw for the dose of 2000 mg/kg bw.
DOSAGE PREPARATION: The required amount of the test item at dose of 2000 mg/kg bw was administered directly. Doses of 300 mg/kg bw were mixed with vehicle shortly before administration. Vehicle was used in this case due to low administration volume/body weight from the point of view of practical realization of small amount aplication. The leftovers of dose preparations were disposed of accordingly to valid standard operation procedures at laboratory facility.
CLASS METHOD
- Rationale for the selection of the starting dose: Available information indicated that the test item was likely to be non-toxic regarding acute toxicity. A limit dose of 2000 mg/kg body weight was therefore used as a starting dose. - Doses:
- 2000 and 300 mg/kg bw.
- No. of animals per sex per dose:
- 3 female rats (2000 mg/kg) and 6 female rats (300 mg/kg)
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Animals were observed individually immediately after administration of the test item and 0.5, 1, 2, and 4 hours later. Each animal was inspected daily for the next 14 days. Individual weights of animals were measured immediately prior to test item administration and weekly thereafter.
- Necropsy of survivors performed: yes
- Clinical signs including body weight: changes in skin, fur, eyes, mucous membranes, respiratory, circulatory, autonomic and central nervous systems, somatomotor activity, and behavioural pattern. Particular attention was given to potential neurologic endpoints such as tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma.
Results and discussion
Effect levelsopen allclose all
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 300 - <= 2 000 mg/kg bw
- Based on:
- test mat.
- Key result
- Sex:
- female
- Dose descriptor:
- LD50 cut-off
- Effect level:
- 500 mg/kg bw
- Based on:
- test mat.
- Mortality:
- Mortality of 3/3 females at limit dose of 2000 mg/kg body weight.
Mortality of 1/6 females at dose of 300 mg/kg body weight.
At 2000 mg/kg the test item caused mortality of all animals within the day of administration. In a second step, 3 females were treated at dose of 300 mg/kg and no mortality was observed during 14-days observing period. In the next step the dose of 300 mg/kg caused death of one animal within the day of administration. - Clinical signs:
- other: At the dose of 2000 mg/kg lethargy, vasodilatation, dyspnoea and spasms were observed in the animals before dying. In the second step, dose of 300 mg/kg did not cause signs of toxicity, change of health or any other adverse reactions. In the next step at
- Gross pathology:
- At the dose of 2000 mg/kg only autolytic changes were observed in 2 animals.
At the dose of 300 mg/kg the animal found dead had several 1-5 mm hemorrhages scattered areas in the lungs and rigor mortis (stiffening) occurred almost simultaneously with death. No macroscopic findings were observed in remaining animals at this dosage.
Any other information on results incl. tables
Table 1. Clinical Observations – 2000 mg/body weight, rats No. 1, 2, 3
Observation |
Time After Administration |
||||||||||||||||||
Hour |
Day |
||||||||||||||||||
I |
0.5 |
1 |
2 |
4 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
|
Skin and Hair** |
- |
1,2,3 |
1,3 |
1,3 |
1,3 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Eyes |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Mucosa |
- |
- |
- |
- |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Respiratory System* |
2 |
- |
1,3 |
1,3 |
1,3 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Circulatory System |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
CNS |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Somatomotoric Activity |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Tremor |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Spasms |
- |
3 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Salivation |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Diarrhoea |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Lethargy |
1,2,3 |
1,3 |
1,3 |
1,3 |
1,3 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Sleep |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Coma |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Death |
- |
2 |
- |
- |
1,3 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Sacrificed |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Others |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
-No observed signs, I- immediately, *-dyspnoe, **-vein vasodilatation in hindlimb soles and tail
Sex |
Dose |
ID |
Administration Result |
Clinical Observation |
♀ |
2000 mg/kg |
1 |
death |
·lethargy immediately and dyspnoe from the first hour after administration of the test item until death (within the day of the test item administration) ·vein vasodilatation in hindlimb soles and tail occurred after half an hour until death |
2 |
death |
·lethargy and dyspnoe immediately after administration of the test item until death (within half an hour after administration of the test item) ·vein vasodilatation in hindlimb soles and tail occurred after half an hour until death |
||
3 |
death |
·lethargy immediately and dyspnoe from the first hour after administration of the test item until death (within the day of the test item administration) ·spasms occurred within half an hour after administration of the test item and lasted 30 seconds in lateral recumbency ·vein vasodilatation in hindlimb soles and tail occurred after half an hour until death |
Table 2. Clinical Observations – 300 mg/body weight, rats No. 4, 5, 6
Observation |
Time After Administration |
||||||||||||||||||
Hour |
Day |
||||||||||||||||||
I |
0.5 |
1 |
2 |
4 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
|
Skin and Hair |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Eyes |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Mucosa |
- |
- |
- |
- |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Respiratory System |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Circulatory System |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
CNS |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Somatomotoric Activity |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Tremor |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Spasms |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Salivation |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Diarrhoea |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Lethargy |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Sleep |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Coma |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Death |
- |
2 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Sacrificed |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Others |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
-No observed signs, I- immediately.
Sex |
Dose |
ID |
Administration Result |
Clinical Observation |
♀ |
300 mg/kg |
4 |
alive |
·no signs of intoxication, nor adverse reactions during the 14-day observation period |
5 |
alive |
·no signs of intoxication, nor adverse reactions during the 14-day observation period |
||
6 |
alive |
·no signs of intoxication, nor adverse reactions during the 14-day observation period |
Table 3. Clinical Observations – 300 mg/body weight, rats No. 7, 8, 9
Observation |
Time After Administration |
||||||||||||||||||
Hour |
Day |
||||||||||||||||||
I |
0.5 |
1 |
2 |
4 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
|
Skin and Hair** |
- |
7,9 |
9 |
9 |
9 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Eyes |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Mucosa |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Respiratory System* |
7,8 |
8,9 |
8 |
8 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Circulatory System |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
CNS |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Somatomotoric Activity |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Tremor |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Spasms |
7 |
9 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Salivation |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Diarrhoea |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Lethargy |
7,8 |
8,9 |
8,9 |
8,9 |
8,9 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Sleep |
- |
- |
9 |
9 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Coma |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Death |
- |
7 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Sacrificied |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
Others |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
-No observed signs, I- immediately, *-dyspnoe, **-vein vasodilatation in hindlimb soles and tail
Sex |
Dose |
ID |
Administration Result |
Clinical Observation |
♀ |
300 mg/kg |
7 |
death |
·dyspnoe and lethargy immediately, spasms occurred 10 min after administration of the test item and lasted 20 seconds in lateral recumbency, death half an hour after administration ·vein vasodilatation in hindlimb soles and tail occurred after half an hour until death |
8 |
alive |
·dyspnoe immediately and lasted until the 2nd hour after administration of the test item, lethargy immediately until the 4thhour after administration of the test item |
||
9 |
alive |
·dyspnoe after half an hour after administration of the test item, spams occurred half an hour after administration of the test item and lasted 30 seconds in lateral recumbency, lethargy half an hour until the 4thhour after administration of the test item, sleep after one hour until the 2ndhour after administration ·vein vasodilatation in hindlimb soles and tail occurred after half an hour until the 4thhour after administration |
Table 4. Body weight
Sex |
Dose |
ID |
Body Weight (g) |
Body Weight Difference (g) |
||||
Initial |
Week 1 |
Week 2 |
Week 1-Initial |
Week 2-Initial |
Week 2-Week 1 |
|||
♀ |
2000 mg/kg |
1 |
205 |
- |
- |
- |
- |
- |
2 |
207 |
- |
- |
- |
- |
- |
||
3 |
214 |
- |
- |
- |
- |
- |
||
300 mg/kg |
4 |
188 |
224 |
240 |
36 |
52 |
16 |
|
5 |
200 |
235 |
255 |
35 |
55 |
20 |
||
6 |
178 |
226 |
242 |
48 |
64 |
16 |
||
300 mg/kg |
7 |
195 |
- |
- |
- |
- |
- |
|
8 |
207 |
240 |
246 |
33 |
39 |
6 |
||
9 |
202 |
242 |
252 |
40 |
50 |
10 |
Table 6. Necropsy results
Sex |
Dose |
ID |
Result |
♀ |
2000 mg/kg |
1 |
autolytic changes In this state we cannot describe any changes made by the TI) |
2 |
no visible pathological changes |
||
3 |
autolytic changes |
||
300 mg/kg |
4 |
no visible pathological changes |
|
5 |
no visible pathological changes |
||
6 |
no visible pathological changes |
||
300 mg/kg |
7 |
The lungs scattered areas of several 1-5 mm hemorrhages Rigor mortis (stiffening) occur almost simultaneously with death |
|
8 |
no visible pathological changes |
||
9 |
no visible pathological changes |
Applicant's summary and conclusion
- Interpretation of results:
- other: Category 4 (CLP Regulation EC no. 1272/2008)
- Conclusions:
- The oral LD50 of the test item in female rats was found to be greater than 300 mg/kg bw and lower than 2000 mg/kg bw. The LD50 cut-off of the test item may be considered to be 500 mg/kg bw.
- Executive summary:
The potential acute toxicity of the test item was studied on female Wistar rats, according to OECD TG 423, under GLP conditions. Since available information indicated that the test item was likely to be non-toxic regarding acute toxicity, a first step was performed by administering a single dose of 2000 mg/kg bw test item to three animals by gavage. The test item caused mortality of 3 animals within the day of administration of the test item. In a second step, 3 females were treated at the dose of 300 mg/kg bw. Test item-related mortality was not observed during the 14-days observing period. In the next step the same dose of 300 mg/kg caused death of one animal within the day of administration. At doses of both 2000 and 300 mg/kg lethargy, vasodilatation, dyspnoea and spasms were observed in the animals. The body weight of all surviving animals increased during the study. During necropsy, at the dose of 2000 mg/kg only autolytic changes were observed in 2 animals. At the dose of 300 mg/kg the animal found dead had several 1-5 mm hemorrhages scattered areas in the lungs and rigor mortis (stiffening) occurred almost simultaneously with death. No macroscopic findings were observed in remaining animals at this dosage. Based on the results, the LD50 of the test item is determined to be greater than 300 mg/kg bw and lower than 2000 mg/kg bw. Based on Annex 2d Test Procedure with a Starting Dose of 2000 mg/kg body weight of OECD Guideline 423, it can be concluded that the test item is classified in GHS Category 4 with a LD50 cut off value 500 mg/kg bw.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.